Goldman Sachs’s Cytokinetics CYTK Stock Holding History

Goldman Sachs’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-250,000	Closed	-$16.5M	–	6649
2026 Q1	$16.5M	Buy	250,000 +63,600	+34%	+$4.04M	﹤0.01%	2624
2025 Q4	$11.8M	Buy	+186,400	New	+$11.6M	﹤0.01%	2934
2025 Q2	–	Sell	-10,500	Closed	-$422K	–	6129
2025 Q1	$422K	Buy	+10,500	New	+$483K	﹤0.01%	5284
2024 Q3	–	Sell	-19,400	Closed	-$1.05M	–	5862
2024 Q2	$1.05M	Buy	19,400 +1,400	+8%	+$84.5K	﹤0.01%	4395
2024 Q1	$1.26M	Buy	+18,000	New	+$1.39M	﹤0.01%	4190
2017 Q4	–	Sell	-50,000	Closed	-$725K	–	6388
2017 Q3	$725K	Buy	+50,000	New	+$683K	﹤0.01%	4838
2015 Q3	–	Sell	-75,000	Closed	-$504K	–	7302
2015 Q2	$504K	Hold	75,000	–	–	﹤0.01%	5204
2015 Q1	$509K	Sell	75,000 -25,000	-25%	-$187K	﹤0.01%	5110
2014 Q4	$801K	Buy	+100,000	New	+$429K	﹤0.01%	4819
2014 Q2	–	Sell	-451,900	Closed	-$4.29M	–	6997
2014 Q1	$4.29M	Buy	+451,900	New	+$4.09M	﹤0.01%	3193

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs's CYTK Position: Q2 2026 in Review

Goldman Sachs reduced its Cytokinetics (CYTK) stake by 20% in Q2 2026, selling an estimated $31.9M and leaving 1,761,588 shares worth $150M. The position accounts for 0.01% of the portfolio, ranked #932.

Goldman Sachs first reported a position in CYTK in Q3 2013 and has held it in 50 quarters since. The position peaked at $151M in Q4 2025. 483 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Goldman Sachs held 1,761,588 shares of Cytokinetics worth $150M as of Q2 2026.
Goldman Sachs sold 444,170 Cytokinetics shares in Q2 2026, an estimated $31.9M.
Cytokinetics made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #932 holding.
Goldman Sachs first reported a position in Cytokinetics in Q3 2013 and has held it in 50 quarters since.
Goldman Sachs's Cytokinetics position peaked at $151M in Q4 2025.
483 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.